iCAR-ILC-N101 / National Cancer Center Hospital East - LARVOL DELTA

First in human trial of off-the shelf iPS derived anti-GPC3 NK cells for recurrent ovarian clear cell carcinoma with peritoneal dissemination (AACR 2022) - "The iCAR-ILC-N101 is an allogeneic human leukocyte antigen (HLA)-homozygous induced pluripotent stem cell (iPSC)-derived anti-glypican-3 (GPC3) CAR-expressing innate lymphoid cells/natural killer cell (ILC/NK), which has both antigen-specific and NK activating receptor-mediated cytotoxicity...No dose-limiting toxicity was observed. Clinical trial registry number: jRCT2033200431"

P1 data • Gastrointestinal Cancer • Hepatoblastoma • Hepatocellular Cancer • Oncology • Ovarian Cancer • Solid Tumor • GPC3